← Leaderboards
Andrew Frisch
University Of Pittsburgh At Pittsburgh
$92,788
Attributed
$92,788
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46.8K · FY2021–22$50K$37.5K$25K$12.5K$0
'21
'22
Funding mix
By agency
NIH$92,788 · 1
By mechanism
F31$92,788 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Dario Aa Vignali$40,087,127
- Steven J Hughes$2,808,835
- Angus W Thomson$32,884,902
- Deborah J. Nelson$14,424,393
- Hassane M Zarour$16,372,397
Others in their field
Other Emerging Leaders on “Adoptive Transfer”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
- Colin Masters · University Of Melbourne$10,651,748
- Akila Subramaniam · University Of Alabama At Birmingham$6,547,544
- Sarah Emily Snider · Beam Diagnostics, Inc.$5,670,978
- Pradeep Natarajan · Massachusetts General Hospital$4,959,712
Research focus
Adoptive TransferAffectAnti-CancerAntigen-Specific T CellsAntitumor ResponseBiologicalCancer TherapyCell CountCell PhysiologyCell RespirationCellsCell SurvivalCell TherapyCellular Metabolic ProcessClinical ApplicationClinical DevelopmentCombinatorialConfocal MicroscopyCost EffectiveCyclic GmpDichloroacetateDna DamageDown-RegulationAdoptive Cell Transfers
Grant awards (2)
Metabolically improving the generation, function, and persistence of therapeutic T cells for the treatment of cancer$46,752
F31 · FY2022 · CA · contact PI
Metabolically improving the generation, function, and persistence of therapeutic T cells for the treatment of cancer$46,036
F31 · FY2021 · CA · contact PI